Subsequently, a matrix risk model developed in a post hoc analysis of the BeSt study (evaluating MTX-based therapy, including MTX plus infliximab, for recent-onset RA) confirmed these data by identifying baseline CRP level, RF/ACPA status, and in addition erosion score as independent factors for predicting rapid radiographic progression, defined as an increase in Sharp-van der Heijde score ≥ 5 after 1 year [29]. The gene discussed is CRP; the disease is rheumatoid arthritis.